INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Praxis Precision Medicine ( NASDAQ:PRAX )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ( "Praxis" or the "Company" ) PRAX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Praxis Precision Medicine ( NASDAQ:PRAX )
NEW YORK, Aug. 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ( "Praxis" or the "Company" ) PRAX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
BOSTON, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - Praxis Precision Medicine ( NASDAQ:PRAX )
Investors can contact the law firm at no cost to learn more about recovering their losses
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
BOSTON, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
What's Going On With Praxis Precision Medicines Stock Monday? - Praxis Precision Medicine ( NASDAQ:PRAX )
Vormatrigine led to a 56.3% median seizure reduction; 22% had complete seizure control in the final month. 23% of patients discontinued the trial; most adverse events were mild to moderate. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Praxis ( PRAX ) Q2 Loss Widens 90%
Praxis Precision Medicines ( NASDAQ:PRAX ) is a clinical-stage biopharmaceutical company specializing in therapies for central nervous system ( CNS ) disorders. On August 4, 2025, it reported financial results for Q2 FY2025. The most notable news from the release was widening operational losses ( ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, July 02, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( Nasdaq: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, June 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( Nasdaq: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Praxis Precision Medicine ( NASDAQ:PRAX )
Praxis had $472 million in cash as of March 31, expected to fund operations into 2028. Vormatrigine may reach over $1 billion in peak sales for major epilepsy indications. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds ...
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Republic Services ( NYSE:RSG ) , Praxis Precision Medicine ( NASDAQ:PRAX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Seaport Global analyst John Mazzoni initiated coverage on Waste Management, Inc.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, May 02, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( Nasdaq: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, May 02, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
On track for six major study readouts across four programs over the next 12 months ...
Praxis Precision Medicines to Participate in Upcoming April Conferences - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, April 03, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Participate in Upcoming April Conferences
BOSTON, April 03, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, March 24, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
BOSTON, March 24, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, March 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( Nasdaq: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, March 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate - Praxis Precision Medicine ( NASDAQ:PRAX )
Praxis' Essential Tremor study halted after interim data failed to meet efficacy goals. Company holds $469.5 million in cash, funding operations into 2028. Our government trade tracker caught Pelosi's 169% AI winner. Discover how to track all 535 Congress member stock trades today.
Market Whales and Their Recent Bets on PRAX Options - Praxis Precision Medicine ( NASDAQ:PRAX )
Whales with a lot of money to spend have taken a noticeably bearish stance on Praxis Precision Medicine. Looking at options history for Praxis Precision Medicine PRAX we detected 39 trades.
Praxis Precision Medicines, Inc. ( PRAX ) Reports Q4 Loss, Tops Revenue Estimates
Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 0.68% and 1,467.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
BOSTON, Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
IGM Biosciences, Inc. ( IGMS ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Praxis Precision Medicines, Inc. ( PRAX ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What the Options Market Tells Us About Praxis Precision Medicine - Praxis Precision Medicine ( NASDAQ:PRAX )
Investors with a lot of money to spend have taken a bullish stance on Praxis Precision Medicine PRAX. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Ensign Group ( ENSG ) Q4 Earnings and Revenues Beat Estimates
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.36% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, Feb. 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( Nasdaq: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines to Present at Two February Investor Conferences - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Present at Two February Investor Conferences
BOSTON, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025. anticipate four commercial assets by ...
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Dravet syndrome is a genetic developmental and epileptic encephalopathy ( DEE ) often caused by a mutation in ...
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome - Praxis Precision Medicine ( NASDAQ:PRAX )
Dravet syndrome is a genetic developmental and epileptic encephalopathy ( DEE ) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, Nov. 06, 2024 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. ( PRAX ) Reports Q3 Loss, Misses Revenue Estimates
Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of -36.82% and 42.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024 - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
BOSTON, Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines ( PRAX ) Moves 8.4% Higher: Will This Strength Last?
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Praxis Precision Medicines to Participate in Upcoming Investor Conferences - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, Sept. 05, 2024 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday - Philip Morris Intl ( NYSE:PM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for Asana, Inc. ASAN from $14 to $12.
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
BOSTON, Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug - Praxis Precision Medicine ( NASDAQ:PRAX )
On Tuesday, Praxis Precision Medicines Inc. PRAX released topline results for its EMBOLD Phase 2 proof-of-concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy ( DEE ) patients.
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period ...
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine ( PRAX-562 ) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, Mass., Sept. 02, 2024 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines ( PRAX ) Upgraded to Buy: What Does It Mean for the Stock?
Praxis Precision Medicines (PRAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results - Praxis Precision Medicine ( NASDAQ:PRAX )
Praxis Precision Medicines, Inc. PRAX reported a loss for the second quarter on Tuesday. The company posted a quarterly loss of $1.74 per share which beat the analyst consensus estimate for a loss of $2.31 per share.
